|
TANK expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.49176243474858E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.20534742981727E-13 |
| Normal-vs-Stage2 |
5.279800E-02 |
| Normal-vs-Stage3 |
2.80710000000184E-06 |
| Normal-vs-Stage4 |
9.63139999999862E-05 |
| Stage1-vs-Stage2 |
1.232150E-01 |
| Stage1-vs-Stage3 |
2.517400E-01 |
| Stage1-vs-Stage4 |
1.102380E-01 |
| Stage2-vs-Stage3 |
4.226400E-01 |
| Stage2-vs-Stage4 |
6.023200E-01 |
| Stage3-vs-Stage4 |
6.832600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.58111326651078E-12 |
| Normal-vs-AfricanAmerican |
2.003200E-03 |
| Normal-vs-Asian |
1.9455899999965E-05 |
| Caucasian-vs-AfricanAmerican |
2.138000E-01 |
| Caucasian-vs-Asian |
9.861600E-01 |
| AfricanAmerican-vs-Asian |
3.608200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44809999999851E-06 |
| Normal-vs-Female |
8.59312621059871E-13 |
| Male-vs-Female |
1.398950E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.87132597884965E-12 |
| Normal-vs-Age(41-60Yrs) |
1.18220000455693E-09 |
| Normal-vs-Age(61-80Yrs) |
7.162100E-03 |
| Normal-vs-Age(81-100Yrs) |
3.635600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.413600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.876900E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.542400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.680300E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.824600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.686600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.579800E-01 |
| Classical-VS-Follicular |
7.774600E-04 |
| Classical-VS-Other |
7.180800E-01 |
| Classical-VS-Normal |
2.54241072639161E-14 |
| Tall-VS-Follicular |
2.182400E-02 |
| Tall-VS-Other |
6.005800E-01 |
| Tall-VS-Normal |
5.78219999999297E-05 |
| Follicular-VS-Other |
4.227200E-01 |
| Follicular-VS-Normal |
8.250000E-02 |
| Other-VS-Normal |
9.453900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.97359999973979E-07 |
| Normal-vs-N1 |
4.05140000003801E-06 |
| N0-vs-N1 |
3.855400E-01 |
|
|
